Pharma Journalist -

Roche announced that the European Commission (EC) has approved Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy (the Perjeta-based regimen) for…
Read More...

Alcami Corporation announced that it has reached an agreement to be acquired by Madison Dearborn Partners. MDP will acquire a majority ownership position in Alcami from existing…
Read More...

Pharmaceutical Product Development (PPD) and NeoGenomics Laboratories are forming a strategic alliance to provide a seamless and fully integrated global pathology and molecular testing…
Read More...

SMi Reports: There are only 3 places left, in 1 week leading industry experts within the microbiology community will be meeting in San Diego at SMi’s largest Pharmaceutical Microbiology…
Read More...

FORMA Therapeutics and HitGen announced a multiyear research collaboration and license agreement to build and screen proprietary DNA-encoded libraries (DELs). Through this collaborative…
Read More...

Aptar Pharma announced plans to collaborate on the launch of a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases. The digital medicine…
Read More...

Daiichi Sankyo Company announced the launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development (hereafter, the consortium) to research and discover drugs for…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta…
Read More...

Arrowhead Pharmaceuticals announced that it has completed enrollment and dosing of all 5 planned cohorts of healthy adult volunteers in the single-ascending dose portion of its ongoing…
Read More...

Pfizer Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) 10 mg twice-daily (BID) for at least eight weeks, followed by…
Read More...